Bibliography
- Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67
- Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37
- Berger MS, Gullick WJ, Geenfield C, et al. Epidermal growth factor receptors in lung tumours. J Pathol 1987;152:297-307
- Dazzi H, Hastleton PS, Thatcher N, et al. Expression of epidermal growth factor receptor (EGFR) in human lung tumours. Br J Cancer 1986;54:746-9
- Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008;20:162-75
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2005;250:2129-40
- Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
- Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
- Cox G, Vyberg M, Melgaard B, et al. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001;92:480-83
- Hirsch FR, Franklin WA, Veve R, et al. HER2/neu expression in malignant lung tumours. Semin Oncol 2002;29:51-8
- Nakumura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER2 overexpression with prognosis in non-small cell lung cancer: a meta-analysis. Cancer 2005;103:1865-73
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32
- Fukoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trials of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL-1 Trial). J Clin Oncol 2003;21:2237-46
- Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
- Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
- Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer; subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55
- Douillard JY, Kim E, Hirsh V, et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pretreated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02. J Thorac Oncol 2007;2:S305-06
- Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004
- Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor [abstract 7020]. J Clin Oncol 2006;24
- Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-14
- Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44
- Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501
- Bean J, Brennan C, Shih JH, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7
- Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
- Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Sciencexpress. Science 2007;316:1039-43
- Fong T, Morgensztern D, Ramaswamy G. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:303-10
- Mok T, Wu YL, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) (IPASS) [abstract LBA2]. Ann Oncol 2008;1(Suppl 8)
- Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. NEJM 2008;359:366-77
- Erlichman C, Hidalgo M, Boni JP, et al. Phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumours. J Clin Oncol 2006;24:2252-60
- Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-8
- Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65
- Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-70
- Wong KK, Fracasso PM, Bukowski RM, et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. J Clin Oncol 2006;24:3018
- Wong KK. HKI-272 in non-small cell lung cancer. Clin Cancer Res 2007;13:4593s-596s
- Allen LF, Eisman IA, Fry DW, et al. CI-1033, an irreversible pan-ErbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003;30(Suppl 16):65-78
- Calvo E, Tolcher AW, Hammond LA, et al. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day in, 7-day off schedule: a phase 1 pharmacokinetic and food effect study. Clin Cancer Res 2004;10:7112-20
- Neumantis J, Eiseman I, Cunningham C, et al. Phase 1 clinical and pharmacokinetic evaluation of CI-1033 in patients with refractory cancer. Clin Cancer Res 2005;11:3846-53
- Zinner RG, Neumantis J, Eiseman I, et al. Phase 1 clinical and pharmacodynamic evaluation of CI-1033 in patients with refractory cancer. Clin Cancer Res 2007;13:3006-14
- Simon GR, Garrett CR, Olson SC, et al. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor. Results of a phase 1 pharmacokinetic study. Clin Cancer Res 2006;12:4645-51
- Shin D, Nemunaitis J, Zinner RG, et al. A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors [abstract 324]. Proc Am Soc Clin Oncol 2001;20:82a
- Garland LL, Hidalgo M, Mendelson DS, et al. A phase 1 clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumours. Clin Cancer Res 2006;12:4274-82
- Chiappori AA, Ellis PM, Hann JT, et al. A phase 1 evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006;1:1010-19
- Janne PA, von Pawel J, Cohen RB, et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non–small-cell lung cancer. J Clin Oncol 2007;25:3936-44
- Shaw H, Plummer R, Vidal L, et al. A phase 1 dose escalation study of BIBW2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours [abstract 3027]. J Clin Oncol 2006;23:18S
- Spicer J, Calvert H, Vidal L, et al. Activity of BIBW2992, an oral irreversible dual kinase inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR: D7-02 [abstract]. J Thorac Oncol 2002;2:S410
- Spicer J, Harris D, Ang J, et al. A phase 1 study of daily BIBW2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel [abstract 474P]. Ann Oncol 2008;19(Suppl 8):viii-157
- Marshall J, Shapiro GI, Terlizzi E, et al. A phase 1 dose escalation trial of BIBW2992, an irreversible EGFR/HER2 kinase inhibitor, for 20 and 13 days in combination with docetaxel every 21 day [abstract 475P]. Ann Oncol 2008;19(Suppl 8):viii-158
- Yang C, Shih J, Chao C, et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: preliminary results of a single-arm phase II clinical trial [abstract 8026]. J Clin Oncol 2008;26
- Hoekstra R, Dumez H, Eskens F. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2006;11:6908-915
- Smylie M, Blumenschein GR, Dowlati A, et al. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioalveolar carcinoma (BAC) or no smoking history [abstract 7611]. J Clin Oncol 2007;25
- Janne PA, Schellens JH, Engleman JA, et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC [abstract 8027]. J Clin Oncol 26:2008;20(Suppl)
- Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res 2002;62:4645-55
- Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumours. Ann Oncol 2005;16:1391-7
- Natale R, Bodkin D, Govindan B, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial [abstract 7000]. J Clin Oncol 2006;24
- Heymach JV, Paz-arez L, De-braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008: published online, doi:10.1200/JCO.2008.17.3138
- Arnold MA, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy. J Clin Oncol 2007;25:4278-84
- Waklee HA, Adeji AA, Halsey J, et al. A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies [abstract 3044]. J Clin Oncol 2006;24
- Rizvi N, Kris MG, Miller V, et al. A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations. J Thorac Oncol 2007;2:S737
- Baselga J, Rojo F, Dumez H, et al. Phase 1 study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regime [abstract 3028]. J Clin Oncol 2005;23